Carboplatin trials for Triple Negative Breast Cancer
All Carboplatin trials · All Triple Negative Breast Cancer trials
10
Recruiting trials
Phase breakdown
Phase 1 2Phase 2 8Phase 3 1
Recruiting trials studying Carboplatin for Triple Negative Breast Cancer
- A Study of LY4175408 in Participants With Advanced Cancer
- A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- MicroRNA Profiles in Triple Negative Breast Cancer
- NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
- Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Common questions
How many trials study Carboplatin for Triple Negative Breast Cancer?
10 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.